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Background. The first European rotavirus surveillance network, EuroRotaNet, comprising 16 laboratories in
15 European countries, has been established.
Methods. Fecal samples from gastroenteritis cases positive for group A rotavirus antigen were collected from
multiple European countries from 2005 to mid-2008 and were subjected to G and P genotyping. Epidemiological
data collected included age, sex, geographical location, setting, dates of onset and sample collection, and clinical
symptoms.
Results. A total of 8879 rotavirus-positive samples were characterized: 2129 cases were from the 2005–2006
season, 4030 from the 2006–2007 season, and 2720 from the ongoing 2007–2008 season. A total of 30 different
G and P type combinations of strains circulated in the region from 2005 through 2008. Of these strains, 90% had
genotypes commonly associated with human infections—G1P[8], G2P[4], G3P[8], G4P[8], and G9P[8]—and
1.37% represented potential zoonotic introductions. G1P[8] remained the most prevalent genotype in Europe as
a whole, but the incidence of infection with G1P[8] rotavirus strains was !50% overall, and all 3 seasons were
characterized by a significant diversity of cocirculating strains. The peak incidence of rotavirus infection occurred
from January through May, and 81% of case patients were aged !2.5 years.
Conclusions. Data gathered through EuroRotaNet will provide valuable background information on the ro-
tavirus strain diversity in Europe before the introduction of rotavirus vaccines, and the network will provide a
robust method for surveillance during vaccine implementation.
The European Rotavirus Network (EuroRotaNet) was
established in January 2007 to gather comprehensive in-
formation on the rotavirus genotypes cocirculating
throughout Europe. Surveillance is achieved through the
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establishment of national networks for sampling and the
use of standardized methods for strain characterization.
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The specific aims of EuroRotaNet are the following: (1) to
develop methods and algorithms for effective rotavirus typing
(G and P) and characterization (including VP6 and NSP4 ge-
notypes); (2) to monitor the effectiveness of current genotyping
methods and to respond to changes associated with genetic
drift and shift; (3) to describe in detail the molecular epide-
miology of rotavirus infections in Europe during consecutive
rotavirus seasons, through genotyping of rotavirus-positive
samples collected throughout each country; (4) to monitor the
emergence and spread of novel rotavirus strains throughout
Europe; and (5) to develop the infrastructure that may inform
future surveillance activities and nested studies for evaluation
of (a) the effectiveness of rotavirus vaccines in the general
population, through monitoring the reduction in disease as-
sociated with common rotaviruses, and (b) the possible vac-
cine-induced emergence of antibody-escape mutants, genotypes
other than those included in the vaccine, and/or reassortants
of vaccine and naturally circulating wild-type strains. This ar-
ticle reports the data collected through EuroRotaNet to date.
MATERIALS AND METHODS
Study area. Currently, the EuroRotaNet database holds data
from 19 European countries. In 2007, the study area consisted
initially of 11 European countries, including Denmark, Finland,
France, Germany, Hungary, Italy, The Netherlands, Slovenia,
Spain, Sweden, and the United Kingdom. An additional 3 Eu-
ropean countries, Belgium, Bulgaria, and Lithuania, joined in
2008, and Greece and Romania joined in January 2009. In
addition, data from countries that are not formal members of
EuroRotaNet, including Azerbaijan, Georgia, Portugal, Tajikis-
tan, and Ukraine, were uploaded to the database. The database
contains data from hospitalized cases and from cases in the
community, collected from rural and urban populations. The
minimum number of samples that each country needs to test
to be able to detect strains circulating with an incidence of 1%
has been calculated from data obtained in previous studies [1,
2] and has been set as a target for rotavirus characterization
in each country.
Sample collection. Fecal samples submitted for investiga-
tion of gastroenteritis that tested positive for group A rotavirus
antigen were collected for genotyping. Hospitals, pediatricians,
and general medical practitioners in the community who were
willing to participate in the surveillance over several years were
identified in each of the participating countries to allow valid
comparisons to be made between each rotavirus season and
within each member country. The denominator of the number
of children aged !5 years in each catchment area is provided
whenever possible. Although rotavirus is investigated as a cause
of gastroenteritis mainly in children aged !5 years, no age limit
has been set. This is important because the emergence of novel
strains is often associated with infection and disease in older
individuals [1].
Epidemiological data. Data including age, sex, geograph-
ical location, setting (hospital or community), dates of onset
and sample collection, and clinical symptoms (diarrhea and/or
vomiting or other symptoms) were collected and linked to the
genotyping data.
Genotyping and strain characterization. Rotavirus strains
were genotyped to identify their G and P types [1, 2]. Rotavirus
VP6 subgroups and NSP4 genotypes were determined for un-
common or novel strains identified through G and P typing,
to identify possible zoonotic transmission [3]. The testing al-
gorithm and genotyping methods are available on the Euro-
RotaNet Web site (http://www.eurorota.net/).
The majority of EuroRotaNet participants have ample ex-
perience with rotavirus characterization, and genotyping is per-
formed by a designated laboratory in each country (there are
2 designated laboratories in Spain). Quality assurance was de-
termined by circulation of blinded panels of well-characterized
rotavirus strains to all participants on a yearly basis to ensure
comparability of data.
Data sharing and analysis. A Web-accessible database
(http://www.eurorota.net/) was developed by the Health Pro-
tection Agency to provide a central portal for dissemination of
network information and for submission and interrogation of
disparate surveillance data. The public interface provides un-
restricted access to information on EuroRotaNet, as well as on
rotavirus, rotavirus characterization methods, and relevant
publications and links to other related sites of interest. Partic-
ipants in the network have password-protected access to ro-
tavirus strain types, epidemiological data, analysis tools, and a
bulletin board to facilitate communication among network
members. Analytical tools have been developed to query the
online database, which allows real-time analysis of the distri-
bution of rotavirus genotypes temporally, geographically (by
country), or by age, sex, or setting (hospital or community).
The data can be analyzed and compared according to calendar
year or rotavirus season (September–August). Other tools, such
as geographical analysis, are currently being developed.
RESULTS
The database contains 14,315 entries from a total of 19 Eu-
ropean countries, and more than one-half (62%) of the entries
are rotavirus strains collected from 2005 through 2008. Historic
data go back to 1991 and are mostly from the United Kingdom.
A total of 2129 cases were from the 2005–2006 season, 4030
were from the 2006–2007 season, and 2720 were from the
ongoing 2007–2008 season (see Table 1 for a detailed break-
down of the countries included each season). Data from 2007–
2008 were preliminary at the time that the manuscript of this
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Table 1. Distribution of Rotavirus Genotypes in the EuroRotaNet Database during 3 Consecutive
Rotavirus Seasons from 2005 through 2008 in 19 Countries
Strain group, genotype
No. (%) of strains for season
2005–2006a
( )n p 2129
2006–2007b
( )n p 4030
2007–2008c
( )n p 2720
Total
( )n p 8879
Common human strains 1939 (91.08) 3552 (88.14) 2514 (92.43) 8005 (90.16)
G1P[8] 922 (43.31) 1686 (41.84) 1690 (62.13) 4298 (48.41)
G2P[4] 51 (2.40) 598 (14.84) 175 (6.43) 824 (9.28)
G3P[8] 81 (3.80) 125 (3.10) 128 (4.71) 334 (3.76)
G4P[8] 90 (4.23) 377 (9.35) 190 (6.99) 657 (7.40)
G9P[8] 795 (37.34) 766 (19.01) 331 (12.17) 1892 (21.31)
Reassortants of common human strains 25 (1.17) 41 (1.02) 16 (0.59) 82 (0.92)
G1P[4] 2 (0.09) 13 (0.32) 8 (0.29) 23 (0.26)
G2P[8] 17 (0.80) 22 (0.55) 6 (0.22) 45 (0.51)
G3P[4] 1 (0.05) 1 (0.02) 0 (0) 2 (0.02)
G4P[4] 3 (0.14) 1 (0.02) 1 (0.04) 5 (0.06)
G9P[4] 2 (0.09) 4 (0.10) 1 (0.04) 7 (0.08)
Potential zoonotic strains 40 (1.88) 56 (1.39) 26 (0.96) 122 (1.37)
G1P[6] 3 (0.14) 0 (0) 0 (0) 3 (0.03)
G2P[6] 1 (0.05) 4 (0.10) 1 (0.04) 6 (0.07)
G3P[6] 1 (0.05) 0 (0) 0 (0) 1 (0.01)
G3P[9] 0 (0) 1 (0.02) 1 (0.04) 2 (0.02)
G4P[6] 6 (0.28) 5 (0.12) 0 (0) 11 (0.12)
G4P[14] 1 (0.05) 0 (0) 0 (0) 1 (0.01)
G6P[8] 0 (0) 0 (0) 2 (0.07) 2 (0.02)
G6P[9] 0 (0) 4 (0.10) 0 (0) 4 (0.04)
G6P[11] 0 (0) 1 (0.02) 0 (0) 1 (0.01)
G8P[4] 2 (0.09) 0 (0) 1 (0.04) 3 (0.03)
G8P[6] 0 (0) 4 (0.10) 1 (0.04) 5 (0.06)
G8P[8] 1 (0.05) 2 (0.05) 1 (0.04) 4 (0.04)
G8P[14] 2 (0.09) 0 (0) 0 (0) 2 (0.02)
G9P[6] 4 (0.19) 5 (0.12) 0 (0) 9 (0.10)
G9P[9] 0 (0) 1 (0.02) 0 (0) 1 (0.01)
G10P[6] 1 (0.05) 1 (0.02) 0 (0) 2 (0.02)
G10P[8] 2 (0.09) 0 (0) 2 (0.07) 4 (0.04)
G10P[14] 0 (0) 5 (0.12) 0 (0) 5 (0.06)
G10P[4] 0 (0) 1 (0.02) 1 (0.04) 2 (0.02)
G12P[6] 0 (0) 4 (0.10) 3 (0.11) 7 (0.08)
G12P[8] 16 (0.75) 18 (0.45) 13 (0.48) 47 (0.53)
Partially typed strains 100 (4.7) 150 (3.72) 104 (3.82) 354 (3.99)
Mixed types 25 (1.17) 231 (5.73) 60 (2.21) 316 (3.56)
NOTE. Data for 2007–2008 include only entries received up to the end of May 2008; entries for which epidemiological
data were not available were excluded. Statistically significant ( ) changes in the genotype distribution from oneP ! .001
season to the next are shown in bold font.
a Includes data from Bulgaria, Denmark, France, Germany, Lithuania, The Netherlands, Portugal, Slovenia, Spain, and
the United Kingdom.
b Includes data from Azerbaijan, Bulgaria, Denmark, Finland, France, Georgia, Hungary, Italy, The Netherlands, Slovenia,
Spain, Sweden, Tajikistan, Ukraine, and the United Kingdom.
c Includes data from Belgium, Denmark, France, Hungary, Italy, The Netherlands, Slovenia, Spain, Sweden, and the
United Kingdom.
article was prepared, and we include entries submitted up to
the end of May 2008.
Temporal distribution of rotavirus infections in Europe.
The 2006–2007 rotavirus season was delayed in relation to the
previous and subsequent seasons (Figure 1). In 2005–2006 and
2007–2008, the highest number of rotavirus infections was de-
tected in February, whereas in 2006–2007, the peak was in April,
and a significant number of infections was detected in May.
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Figure 1. Temporal distribution of rotavirus infections during 3 con-
secutive rotavirus seasons, 2005–2008. Total numbers of cases analyzed
were 2129, 4030, and 2720 for the 2005–2006, 2006–2007, and 2007–
2008 seasons, respectively (data for 2007–2008 represent entries
uploaded to the database by the end of May 2008).
Differences in the month in which rotavirus infections
peaked were observed across the EuroRotaNet countries. The
earliest peaks were detected in Spain in January, and in Italy
in March. In France and the United Kingdom, the incidence
of infection peaked in April, and in the Scandinavian countries
and in Hungary and Slovenia, the peak of infection was in May
(Table 2).
Genotype distribution. The most common rotavirus ge-
notype detected during the 3 rotavirus seasons from 2005
through 2008 was G1P[8] (Table 2). However, in 2005–2006
and 2006–2007, G1P[8] represented !50% of the strains co-
circulating in Europe, and this increased significantly to 62%
in 2007–2008 ( ). All 3 seasons were characterized by aP ! .001
high diversity of cocirculating strains, resulting in a relatively
high percentage of mixed infections (3.5%). The second most
common genotype during the 3 seasons was G9P[8]; however,
the percentage of this genotype decreased significantly from
season to season ( ). The percentage of G2P[4] strainsP ! .001
increased significantly in 2006–2007 and then decreased sig-
nificantly in 2007–2008 ( ). The incidence of infectionP ! .001
with G3P[8] strains remained stable during the 3 consecutive
seasons, whereas significant differences were observed from sea-
son to season in the incidence of infection with G4P[8] strains
( ). G12P[8] strains were detected in several EuropeanP ! .001
countries, with a relatively low incidence of infection with these
strains during the 2005–2006 season, and the incidence re-
mained similar through 2007–2008 (Table 2).
The relative incidence of infection with the various genotypes
differed among the participating countries and among seasons
(Table 3). G1P[8] was the most common genotype in Denmark,
France, the United Kingdom, and Slovenia during each of the
3 rotavirus seasons, although the relative incidence of infection
with G1P[8] strains varied from season to season (Table 3). In
addition, the incidence of infection with G2P[4] strains in-
creased significantly in 2006–2007 in these 4 countries, and
decreased again in 2007–2008. In Spain, G9P[8] strains were
the most prevalent in the 2005–2006 and 2006–2007 seasons,
but the incidence of infection with these strains decreased sig-
nificantly in 2007–2008, whereas G1P[8] became the most prev-
alent genotype in 2007–2008, representing 84.7% of strains.
G2P[4] strains were present at constant low levels during the
3 seasons in Spain.
Epidemiological characteristics. Most of the symptomatic
rotavirus infections in Europe for which samples were collected
occurred in children aged !2.5 years (4263 [81.5%] of 5228
case patients for whom age was available), with the peak be-
tween 6 and 18 months of age (2463 [47.1%]). Smaller numbers
of infections were reported among children aged 2.5–7 years
(736 [14.1%]), young adults (59 [1.1%]), and elderly persons
(114 [2.2%]). No significant differences were seen in the dis-
tribution of genotypes according to age (data not shown).
No significant differences were seen in the incidence of ro-
tavirus infections reported in male and female individuals (55%
and 45% of 5805 individuals, respectively), and no differences
were observed in the distribution of genotypes between the
sexes (data not shown).
Of 7081 rotavirus infections in 2005–2008 for which the
setting was recorded, 65% were hospitalized cases and 35%
were community cases. The percentages of the different ge-
notypes detected in hospital or community cases followed the
same distribution, with the exception of G2P[4] strains, which
were found significantly more often in hospitalized cases
( ; data not shown).P ! .001
DISCUSSION
EuroRotaNet provides consistent and comparable data on ro-
tavirus strain diversity across Europe through national networks
for sampling and the use of standardized methods for strain
characterization. Rotavirus infections are nonnotifiable, and
this network has no influence on the national surveillance of
rotavirus infections in the different European countries. How-
ever, the data obtained in this study should be representative
of the strains circulating in each of the countries and provide
a more robust comparison among countries and seasons than
do data from small, isolated, and country-centric studies pub-
lished previously.
Analysis of the EuroRotaNet database revealed that, for the
3 rotavirus seasons from 2005 through 2008, G1P[8] remained
the most prevalent genotype in Europe as a whole, but the
incidence of infection with G1P[8] strains remained !50%. All
3 seasons were characterized by a significant diversity of co-
circulating strains. Recently, an increase in the incidence of
infection with G2P[4] rotavirus strains has been reported in
Brazil, where the monovalent G1P[8] rotavirus vaccine is cur-
rently being used [4, 5]. This finding raises questions about
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Table 2. Distribution of Rotavirus Infections by Month in Different European Regions during the 2006–2007
Season
Month
No. (%) of rotavirus infections
Spain
( )n p 601
Italy
( )n p 317
France
( )n p 521
United Kingdom
( )n p 831
Hungary and Slovenia
( )n p 629
Scandinaviaa
( )n p 323
September 5 (0.8) 0 (0.0) 1 (0.2) 2 (0.2) 2 (0.3) 3 (0.9)
October 18 (3.0) 1 (0.3) 3 (0.6) 0 (0.0) 0 (0.0) 2 (0.6)
November 31 (5.2) 7 (2.2) 2 (0.4) 8 (1.0) 2 (0.3) 5 (1.5)
December 91 (15.1) 11 (3.5) 23 (4.4) 2 (0.2) 12 (1.9) 2 (0.6)
January 154 (25.6) 30 (9.5) 39 (7.5) 42 (5.1) 6 (1.0) 7 (2.2)
February 49 (8.2) 40 (12.6) 95 (18.2) 95 (11.4) 70 (11.1) 20 (6.2)
March 90 (15.0) 176 (55.5) 139 (26.7) 265 (31.9) 113 (18.0) 49 (15.2)
April 32 (5.3) 21 (6.6) 169 (32.4) 281 (33.8) 120 (19.1) 87 (26.9)
May 76 (12.6) 13 (4.1) 44 (8.4) 91 (11.0) 204 (32.4) 92 (28.5)
June 29 (4.8) 5 (1.6) 3 (0.6) 28 (3.4) 53 (8.4) 41 (12.7)
July 19 (3.2) 3 (0.9) 3 (0.6) 8 (1.0) 21 (3.3) 10 (3.1)
August 7 (1.2) 10 (3.2) 0 (0.0) 9 (1.1) 26 (4.1) 5 (1.5)
NOTE. Entries for which epidemiological data were incomplete were excluded. The highest number of infections for each
geographic region is shown in bold font. Data for the 2007–2008 season were not included because they were not yet complete.
a Data for Scandinavia include data for Denmark, Faero Islands, and Finland.
the ability of this vaccine to confer cross-protection against
G2P[4] rotavirus disease and the possibility that the increased
incidence of infection with rotavirus of this genotype is being
driven by the introduction of the vaccine. However, data from
the EuroRotaNet network indicated a significant increase in the
incidence of infection with G2P[4] rotavirus strains during the
2006–2007 season, compared with the 2005–2006 season, in
the absence of a vaccination program. Therefore, the findings
in Brazil may represent normal fluctuation in the interseasonal
diversity of strains rather than vaccine-driven selection, as has
been reported previously [1, 2]. Interestingly, G2P[4] rotavirus
infections in Europe were significantly associated with hospital
cases and are possibly associated with more-severe disease. The
reemergence of G2P[4] strains has previously been associated
with mutations within antigenic sites on the VP7 gene leading
to the emergence of antibody escape mutants [6–8], and this
may also explain the association of G2P[4] strains with more-
severe disease.
Significant differences were also observed in the relative in-
cidences of infection with the various rotavirus genotypes
among countries (Table 3). The incidence of infection with
strains of zoonotic origin fluctuated between 0% and 7.8%
among these 5 countries. Remarkably, Denmark reported the
highest incidence of infection with such strains in 2005–2006,
but none were reported in the subsequent seasons. Further
analysis of these data should clarify whether the high incidence
reported in 2005–2006 was limited to a particular location and/
or represented an outbreak. Interestingly, 1.34% of all strains
in the database from 2005 through 2008 had unusual G and/
or P types, suggesting either direct zoonotic transmission or
reassortment between zoonotic and human strains, as previ-
ously documented [1, 3, 9–15].
If extrapolated across the 14 European countries, with an
estimated 3,579,070 cases of rotavirus infection, this would
account for a mean of 47,959 cases of infection with rotavirus
strains of possible zoonotic origin each year. Among these, it
is of note that G9P[6] strains have reemerged in Hungary. G9
strains first emerged in Europe in 1995 as G9P[6] strains and
were likely introduced through zoonosis [1]. Subsequently, the
G9P[8] genotype originated through reassortment with human
strains and spread throughout Europe and the rest of the world
to become a common human strain, displacing G9P[6] strains
[1]. This finding may suggest zoonotic reintroduction of
G9P[6] into Europe, and further investigation suggested that
these strains were imported from India [16]. G12 in combi-
nation with P[6], P[8], or P[9] has been detected among strains
in Europe, although the incidence of infection with these strains
remained relatively low.
The data being gathered through EuroRotaNet will provide
valuable background information on the rotavirus strain di-
versity in Europe before the introduction of rotavirus vaccines,
and the network will provide a robust method for surveillance
during vaccination implementation. Furthermore, because ro-
tavirus vaccination is not being introduced equally across Eu-
rope, comparisons of genotype distributions between neigh-
boring countries with and without universal rotavirus
vaccination programs will be possible. Although still prelimi-
nary, the data collected through EuroRotaNet suggest a south-
to-north and west-to-east pattern of rotavirus spread in Europe.
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work will provide evidence as to whether this is a true and
repetitive phenomenon.
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